The efficacy of modern pharmaceuticals often hinges on the quality and precise synthesis of their constituent chemical intermediates. 1-(3-Ethoxy-4-Methoxyphenyl)-2-(Methylsulfonyl)ethanamine, identified by CAS 253168-94-4, is a prime example of such a critical compound, playing a vital role in the production of Apremilast. As a dedicated manufacturer and supplier of advanced chemical intermediates, we recognize the profound significance of this molecule for the pharmaceutical sector.

The chemical structure of 1-(3-Ethoxy-4-Methoxyphenyl)-2-(Methylsulfonyl)ethanamine lends itself to specific synthetic transformations required for Apremilast. Its properties, such as its crystalline form (white to off-white powder) and solubility characteristics in various organic solvents, are vital considerations for process chemists. Researchers looking to buy this intermediate for their synthesis projects will find that consistent quality is key to reproducible results. Partnering with a reputable supplier in China can provide access to material that meets high purity standards, often exceeding 98%, at a competitive price.

The market for pharmaceutical intermediates is driven by innovation and the constant demand for effective therapeutic agents. Apremilast, used to treat inflammatory conditions, has a significant therapeutic impact, driving the need for reliable sources of its key building blocks. When you purchase CAS 253168-94-4, you are investing in the success of your downstream synthesis and the quality of your final API. We ensure that our offerings meet the stringent requirements of the pharmaceutical industry, providing both quality and quantity.

Our role as a manufacturer and supplier extends beyond just delivering chemicals. We aim to be a strategic partner, supporting your research and development efforts with dependable products and valuable information. Understanding the chemical significance and sourcing reliable suppliers for intermediates like 1-(3-Ethoxy-4-Methoxyphenyl)-2-(Methylsulfonyl)ethanamine is a critical step in bringing new pharmaceutical treatments to market.